Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Severe Hypertriglyceridemia: later-stage trial registry

2 of 9 indexed Severe Hypertriglyceridemia trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Severe Hypertriglyceridemia: 9 US clinical trials tracked, 2 recruiting.

Severe Hypertriglyceridemia is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Arrowhead Pharmaceuticals, running 3 of these trials.

Enrollment posture brief

Registry condition severe-hypertriglyceridemia

OPEN 2 | RECR 22% | LATE 7 | EARLY 2 | RANK #1916 | SPON 3

Nearest open-share peer: Acne (22% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Severe Hypertriglyceride (th…22%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Severe Hypertriglyceridemia

Severe Hypertriglyceridemia lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Severe Hypertriglyceridemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Severe Hypertriglyceridemia is recruiting below its size-band peers.

    2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Severe Hypertriglyceridemia research.

    Arrowhead Pharmaceuticals accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Severe Hypertriglyceridemia enrolment sits around 360 participants.

    Median target enrolment is 360 among the 9 trials that report a genuine target (sentinel values excluded). 2 of those (22.2%) plan for fewer than 100 participants.

  4. Severe Hypertriglyceridemia research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 37

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 288 participants

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Arrowhead Pharmaceuticals

NCT06880770

RECRUITING Phase 2 60 participants

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

Eli Lilly and Company

NCT07269210

ACTIVE NOT RECRUITING Phase 3 885 participants

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Ionis Pharmaceuticals

NCT05681351

ACTIVE NOT RECRUITING Phase 3 446 participants

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals

NCT06347003

ACTIVE NOT RECRUITING Phase 3 360 participants

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

89bio

NCT05852431

ACTIVE NOT RECRUITING Phase 3 311 participants

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals

NCT06347016

COMPLETED Phase 3 551 participants

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Kowa Research Institute

NCT03001817

COMPLETED Phase 3 446 participants

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Ionis Pharmaceuticals

NCT05552326

COMPLETED Phase 2 54 participants

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

AstraZeneca

NCT01208961

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 7

Top Sponsors

Named interventions

Most-linked intervention names on Severe Hypertriglyceridemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
6 trials
Olezarsen Drug
2 trials
Plozasiran Injection Drug
2 trials
Placebo (for Fenofibrate) Drug
1 trials
Placebo (for K-877) Drug
1 trials
Lovaza (4 g) and Epanova (4 g) Drug
1 trials
Epanova (4 g) and Lovaza (4 g) Drug
1 trials
K-877 Drug
1 trials

US sites by state

Facility locations filed on Severe Hypertriglyceridemia trials. A trial with sites in several states counts in each.

California 8 trials
Florida 7 trials
Indiana 5 trials
Illinois 5 trials
Georgia 4 trials
Arizona 4 trials
Maryland 3 trials
Kansas 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Severe Hypertriglyceridemia page

9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Severe Hypertriglyceridemia condition card totals 9 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.